Global Checkpoint Inhibitors for Treating Cancer Market Research Report 2020

Publisher Name :
Date: 01-Jan-2020
No. of pages: 99
Inquire Before Buying

Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the "brakes" on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.

Those four kinds of checkpoint inhibitors are mainly used to treat melanoma, bladder cancer and others. In 2015, melanoma treatment consumed checkpoint inhibitors took a share of 80.53%. In 2016, melanoma treatment consumed checkpoint inhibitors will be 68153g. Bladder cancer treatment consumed checkpoint inhibitors will be 1978g.

The global Checkpoint Inhibitors for Treating Cancer market is valued at 7551.9 million US$ in 2020 is expected to reach 37840 million US$ by the end of 2026, growing at a CAGR of 25.6% during 2021-2026.

This report focuses on Checkpoint Inhibitors for Treating Cancer volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Checkpoint Inhibitors for Treating Cancer market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan etc.

Market Segment Analysis

The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type, the Checkpoint Inhibitors for Treating Cancer market is segmented into

- PD-1 Inhibitors

- PD-L1 Inhibitors

- CTLA-4 Inhibitors

Segment by Application

- Melanoma Treatment

- Bladder Cancer Treatment

- Other

Global Checkpoint Inhibitors for Treating Cancer Market: Regional Analysis

The Checkpoint Inhibitors for Treating Cancer market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.

The key regions covered in the Checkpoint Inhibitors for Treating Cancer market report are:

North America

- U.S.

- Canada

Europe

- Germany

- France

- U.K.

- Italy

- Russia

Asia-Pacific

- China

- Japan

- South Korea

- India

- Australia

- Taiwan

- Indonesia

- Thailand

- Malaysia

- Philippines

- Vietnam

Latin America

- Mexico

- Brazil

- Argentina

Middle East & Africa

- Turkey

- Saudi Arabia

- U.A.E

Global Checkpoint Inhibitors for Treating Cancer Market: Competitive Analysis

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

The major players in global Checkpoint Inhibitors for Treating Cancer market include:

- Bristol-Myers Squibb(BMS)

- Merck

- Roche

Global Checkpoint Inhibitors for Treating Cancer Market Research Report 2020

Table of Contents
1 Checkpoint Inhibitors for Treating Cancer Market Overview
1.1 Product Overview and Scope of Checkpoint Inhibitors for Treating Cancer
1.2 Checkpoint Inhibitors for Treating Cancer Segment by Type
1.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.2.4 CTLA-4 Inhibitors
1.3 Checkpoint Inhibitors for Treating Cancer Segment by Application
1.3.1 Checkpoint Inhibitors for Treating Cancer Sales Comparison by Application: 2020 VS 2026
1.3.2 Melanoma Treatment
1.3.3 Bladder Cancer Treatment
1.3.4 Other
1.4 Global Checkpoint Inhibitors for Treating Cancer Market Size Estimates and Forecasts
1.4.1 Global Checkpoint Inhibitors for Treating Cancer Revenue 2015-2026
1.4.2 Global Checkpoint Inhibitors for Treating Cancer Sales 2015-2026
1.4.3 Checkpoint Inhibitors for Treating Cancer Market Size by Region: 2020 Versus 2026
2 Global Checkpoint Inhibitors for Treating Cancer Market Competition by Manufacturers
2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturers (2015-2020)
2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturers (2015-2020)
2.3 Global Checkpoint Inhibitors for Treating Cancer Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Checkpoint Inhibitors for Treating Cancer Manufacturing Sites, Area Served, Product Type
2.5 Checkpoint Inhibitors for Treating Cancer Market Competitive Situation and Trends
2.5.1 Checkpoint Inhibitors for Treating Cancer Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Checkpoint Inhibitors for Treating Cancer Players (Opinion Leaders)
3 Checkpoint Inhibitors for Treating Cancer Retrospective Market Scenario by Region
3.1 Global Checkpoint Inhibitors for Treating Cancer Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Checkpoint Inhibitors for Treating Cancer Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
3.3.1 North America Checkpoint Inhibitors for Treating Cancer Sales by Country
3.3.2 North America Checkpoint Inhibitors for Treating Cancer Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
3.4.1 Europe Checkpoint Inhibitors for Treating Cancer Sales by Country
3.4.2 Europe Checkpoint Inhibitors for Treating Cancer Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Region
3.5.1 Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region
3.5.2 Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
3.6.1 Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country
3.6.2 Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country
3.6.3 Mexico
3.6.3 Brazil
3.6.3 Argentina
3.7 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
3.7.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country
3.7.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Checkpoint Inhibitors for Treating Cancer Historic Market Analysis by Type
4.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2015-2020)
4.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type (2015-2020)
4.3 Global Checkpoint Inhibitors for Treating Cancer Price Market Share by Type (2015-2020)
4.4 Global Checkpoint Inhibitors for Treating Cancer Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Global Checkpoint Inhibitors for Treating Cancer Historic Market Analysis by Application
5.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
5.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2015-2020)
5.3 Global Checkpoint Inhibitors for Treating Cancer Price by Application (2015-2020)
6 Company Profiles and Key Figures in Checkpoint Inhibitors for Treating Cancer Business
6.1 Bristol-Myers Squibb(BMS)
6.1.1 Corporation Information
6.1.2 Bristol-Myers Squibb(BMS) Description, Business Overview and Total Revenue
6.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Bristol-Myers Squibb(BMS) Products Offered
6.1.5 Bristol-Myers Squibb(BMS) Recent Development
6.2 Merck
6.2.1 Merck Checkpoint Inhibitors for Treating Cancer Production Sites and Area Served
6.2.2 Merck Description, Business Overview and Total Revenue
6.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2015-2020)
6.2.4 Merck Products Offered
6.2.5 Merck Recent Development
6.3 Roche
6.3.1 Roche Checkpoint Inhibitors for Treating Cancer Production Sites and Area Served
6.3.2 Roche Description, Business Overview and Total Revenue
6.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2015-2020)
6.3.4 Roche Products Offered
6.3.5 Roche Recent Development
7 Checkpoint Inhibitors for Treating Cancer Manufacturing Cost Analysis
7.1 Checkpoint Inhibitors for Treating Cancer Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer
7.4 Checkpoint Inhibitors for Treating Cancer Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Checkpoint Inhibitors for Treating Cancer Distributors List
8.3 Checkpoint Inhibitors for Treating Cancer Customers
9 Market Dynamics
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis
10 Global Market Forecast
10.1 Global Checkpoint Inhibitors for Treating Cancer Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Checkpoint Inhibitors for Treating Cancer by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Checkpoint Inhibitors for Treating Cancer by Type (2021-2026)
10.2 Checkpoint Inhibitors for Treating Cancer Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Checkpoint Inhibitors for Treating Cancer by Application (2021-2026)
10.2.2 Global Forecasted Revenue of Checkpoint Inhibitors for Treating Cancer by Application (2021-2026)
10.3 Checkpoint Inhibitors for Treating Cancer Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Checkpoint Inhibitors for Treating Cancer by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Checkpoint Inhibitors for Treating Cancer by Region (2021-2026)
10.4 North America Checkpoint Inhibitors for Treating Cancer Estimates and Projections (2021-2026)
10.5 Europe Checkpoint Inhibitors for Treating Cancer Estimates and Projections (2021-2026)
10.6 Asia Pacific Checkpoint Inhibitors for Treating Cancer Estimates and Projections (2021-2026)
10.7 Latin America Checkpoint Inhibitors for Treating Cancer Estimates and Projections (2021-2026)
10.8 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Estimates and Projections (2021-2026)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Checkpoint Inhibitors for Treating Cancer Sales (g) Growth Rate Comparison by Type (2015-2026)
Table 2. Global Checkpoint Inhibitors for Treating Cancer Sales (g) Comparison by Application: 2020 VS 2026
Table 3. Global Checkpoint Inhibitors for Treating Cancer Market Size by Type (g) (US$ Million) (2020 VS 2026)
Table 4. Global Key Checkpoint Inhibitors for Treating Cancer Manufacturers Covered in This Study
Table 5. Global Checkpoint Inhibitors for Treating Cancer Sales (g) by Manufacturers (2015-2020)
Table 6. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Manufacturers (2015-2020)
Table 7. Global Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) by Manufacturers (2015-2020)
Table 8. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturers (2015-2020)
Table 9. Global Market Checkpoint Inhibitors for Treating Cancer Average Price (USD/mg) of Key Manufacturers (2015-2020)
Table 10. Manufacturers Checkpoint Inhibitors for Treating Cancer Sales Sites and Area Served
Table 11. Manufacturers Checkpoint Inhibitors for Treating Cancer Product Types
Table 12. Global Checkpoint Inhibitors for Treating Cancer Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Checkpoint Inhibitors for Treating Cancer by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Checkpoint Inhibitors for Treating Cancer as of 2019)
Table 14.Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Main Points Interviewed from Key Checkpoint Inhibitors for Treating Cancer Players
Table 16. Global Checkpoint Inhibitors for Treating Cancer Sales (g) by Region (2015-2020)
Table 17. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2015-2020)
Table 18. Global Checkpoint Inhibitors for Treating Cancer Revenue (Million US$) by Region (2015-2020)
Table 19. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2015-2020)
Table 20. North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2015-2020) (g)
Table 21. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2015-2020)
Table 22. North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2015-2020) (US$ Million)
Table 23. North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2015-2020)
Table 24. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2015-2020) (g)
Table 25. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2015-2020)
Table 26. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2015-2020) (US$ Million)
Table 27. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2015-2020)
Table 28. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (2015-2020) (g)
Table 29. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2015-2020)
Table 30. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (2015-2020) (US$ Million)
Table 31. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2015-2020)
Table 32. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2015-2020) (g)
Table 33. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2015-2020)
Table 34. Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2015-2020) (US$ Million)
Table 35. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2015-2020)
Table 36. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2015-2020) (g)
Table 37. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2015-2020)
Table 38. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2015-2020) (US$ Million)
Table 39. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2015-2020)
Table 40. Global Checkpoint Inhibitors for Treating Cancer Sales (g) by Type (2015-2020)
Table 41. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2015-2020)
Table 42. Global Checkpoint Inhibitors for Treating Cancer Revenue (Million US$) by Type (2015-2020)
Table 43. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2015-2020)
Table 44. Global Checkpoint Inhibitors for Treating Cancer Price (USD/mg) by Type (2015-2020)
Table 45. Global Checkpoint Inhibitors for Treating Cancer Sales (g) by Application (2015-2020)
Table 46. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Table 47. Global Checkpoint Inhibitors for Treating Cancer Sales Growth Rate by Application (2015-2020)
Table 48. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Corporation Information
Table 49. Bristol-Myers Squibb(BMS) Description and Business Overview
Table 50. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue (Million US$), Price (USD/mg) and Gross Margin (2015-2020)
Table 51. Bristol-Myers Squibb(BMS) Main Product
Table 52. Bristol-Myers Squibb(BMS) Recent Development
Table 53. Merck Checkpoint Inhibitors for Treating Cancer Corporation Information
Table 54. Merck Corporation Information
Table 55. Merck Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue (Million US$), Price (USD/mg) and Gross Margin (2015-2020)
Table 56. Merck Main Product
Table 57. Merck Recent Development
Table 58. Roche Checkpoint Inhibitors for Treating Cancer Corporation Information
Table 59. Roche Corporation Information
Table 60. Roche Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue (Million US$), Price (USD/mg) and Gross Margin (2015-2020)
Table 61. Roche Main Product
Table 62. Roche Recent Development
Table 63. Sales Base and Market Concentration Rate of Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Checkpoint Inhibitors for Treating Cancer Distributors List
Table 66. Checkpoint Inhibitors for Treating Cancer Customers List
Table 67. Market Key Trends
Table 68. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 69. Key Challenges
Table 70. Global Checkpoint Inhibitors for Treating Cancer Sales (g) Forecast by Type (2021-2026)
Table 71. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Type (2021-2026)
Table 72. Global Checkpoint Inhibitors for Treating Cancer Revenue (Million US$) Forecast by Type (2021-2026)
Table 73. Global Checkpoint Inhibitors for Treating Cancer Revenue (Million US$) Market Share Forecast by Type (2021-2026)
Table 74. Global Checkpoint Inhibitors for Treating Cancer Sales (g) Forecast by Application (2021-2026)
Table 75. Global Checkpoint Inhibitors for Treating Cancer Revenue (Million US$) Forecast by Application (2021-2026)
Table 76. Global Checkpoint Inhibitors for Treating Cancer Sales (g) Forecast by Region (2021-2026)
Table 77. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Region (2021-2026)
Table 78. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2021-2026) (US$ Million)
Table 79. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Region (2021-2026)
Table 80. Research Programs/Design for This Report
Table 81. Key Data Information from Secondary Sources
Table 82. Key Data Information from Primary Sources
List of Figures
Figure 1. Picture of Checkpoint Inhibitors for Treating Cancer
Figure 2. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type: 2020 VS 2026
Figure 3. PD-1 Inhibitors Product Picture
Figure 4. PD-L1 Inhibitors Product Picture
Figure 5. CTLA-4 Inhibitors Product Picture
Figure 6. Global Checkpoint Inhibitors for Treating Cancer Consumption Market Share by Application: 2020 VS 2026
Figure 7. Melanoma Treatment
Figure 8. Bladder Cancer Treatment
Figure 9. Other
Figure 10. Global Checkpoint Inhibitors for Treating Cancer Market Size 2015-2026 (US$ Million)
Figure 11. Global Checkpoint Inhibitors for Treating Cancer Sales Capacity (g) (2015-2026)
Figure 12. Global Checkpoint Inhibitors for Treating Cancer Market Size Market Share by Region: 2020 Versus 2026
Figure 13. Checkpoint Inhibitors for Treating Cancer Sales Share by Manufacturers in 2020
Figure 14. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturers in 2019
Figure 15. The Global 5 and 10 Largest Players: Market Share by Checkpoint Inhibitors for Treating Cancer Revenue in 2019
Figure 16. Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 17. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2015-2020)
Figure 18. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region in 2019
Figure 19. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2015-2020)
Figure 20. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region in 2019
Figure 21. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2019
Figure 22. North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2019
Figure 23. U.S. Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 24. U.S. Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 25. Canada Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 26. Canada Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 27. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2019
Figure 28. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2019
Figure 29. Germany Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 30. Germany Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 31. France Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 32. France Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 33. U.K. Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 34. U.K. Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 35. Italy Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 36. Italy Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Russia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 38. Russia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region in 2019
Figure 40. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region in 2019
Figure 41. China Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 42. China Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 43. Japan Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 44. Japan Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. South Korea Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 46. South Korea Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. India Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 48. India Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. Australia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 50. Australia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Taiwan Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 52. Taiwan Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Indonesia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 54. Indonesia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Thailand Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 56. Thailand Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Malaysia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 58. Malaysia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Philippines Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 60. Philippines Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Vietnam Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 62. Vietnam Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2019
Figure 64. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2019
Figure 65. Mexico Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 66. Mexico Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. Brazil Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 68. Brazil Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Argentina Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 70. Argentina Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2019
Figure 72. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2019
Figure 73. Turkey Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 74. Turkey Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 76. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. U.A.E Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2015-2020) (g)
Figure 78. U.A.E Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Sales Market Share of Checkpoint Inhibitors for Treating Cancer by Type (2015-2020)
Figure 80. Sales Market Share of Checkpoint Inhibitors for Treating Cancer by Type in 2019
Figure 81. Revenue Share of Checkpoint Inhibitors for Treating Cancer by Type (2015-2020)
Figure 82. Revenue Market Share of Checkpoint Inhibitors for Treating Cancer by Type in 2019
Figure 83. Global Checkpoint Inhibitors for Treating Cancer Sales Growth by Type (2015-2020) (g)
Figure 84. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
Figure 85. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2019
Figure 86. Global Revenue Share of Checkpoint Inhibitors for Treating Cancer by Application (2015-2020)
Figure 87. Global Revenue Share of Checkpoint Inhibitors for Treating Cancer by Application in 2020
Figure 88. Bristol-Myers Squibb(BMS) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 89. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 90. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 91. Price Trend of Key Raw Materials
Figure 92. Manufacturing Cost Structure of Checkpoint Inhibitors for Treating Cancer
Figure 93. Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer
Figure 94. Checkpoint Inhibitors for Treating Cancer Industrial Chain Analysis
Figure 95. Channels of Distribution
Figure 96. Distributors Profiles
Figure 97. Porter's Five Forces Analysis
Figure 98. North America Checkpoint Inhibitors for Treating Cancer Sales (g) and Growth Rate Forecast (2021-2026)
Figure 99. North America Checkpoint Inhibitors for Treating Cancer Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 100. Europe Checkpoint Inhibitors for Treating Cancer Sales (g) and Growth Rate Forecast (2021-2026)
Figure 101. Europe Checkpoint Inhibitors for Treating Cancer Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 102. Latin America Checkpoint Inhibitors for Treating Cancer Sales (g) and Growth Rate Forecast (2021-2026)
Figure 103. Latin America Checkpoint Inhibitors for Treating Cancer Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 104. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales (g) and Growth Rate Forecast (2021-2026)
Figure 105. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 106. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales (g) and Growth Rate Forecast (2021-2026)
Figure 107. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 108. Bottom-up and Top-down Approaches for This Report
Figure 109. Data Triangulation
Figure 110. Key Executives Interviewed
  • 2020 Cancer Diagnostic Testing: A Market on the Verge of Explosion--US, Europe, Japan--Supplier Shares and Market Segment Forecasts by Test--Technological Breakthroughs, Emerging Tests, Competitive Analysis
    Published: 18-Feb-2020        Price: US 24500 Onwards        Pages: 1200
    VPGMarketResearch's new report is a study of the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppli......
  • Global PSA Test Market Growth 2020-2025
    Published: 11-Feb-2020        Price: US 3660 Onwards        Pages: 161
    According to this study, over the next five years the PSA Test market will register a 10.8% CAGR in terms of revenue, the global market size will reach $ 698.1 million by 2025, from $ 463.4 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in PSA Test business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of PSA Test market by type, application, key manufa......
  • Succeeding in the 2020 Global Cancer Diagnostics Market: US, Europe, Japan--Supplier Shares and Sales Segment Forecasts by Test and Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities
    Published: 10-Feb-2020        Price: US 27500 Onwards        Pages: 1200
    LeadingMarketResearch.com's new report is a seven-country strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the U.S., five major European countries (France, Germany, Italy, Spain, UK) and Japan; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading market......
  • Succeeding in the 2020 Europe Cancer Diagnostics Market: France, Germany, Italy, Spain, UK--Supplier Shares and Sales Segment Forecasts by Test and Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities
    Published: 10-Feb-2020        Price: US 17500 Onwards        Pages: 820
    LeadingMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in major European countries (France, Germany, Italy, Spain, UK); reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading market players and potential entrants; and su......
  • Succeeding in the 2020 France Cancer Diagnostics Market: Supplier Shares and Sales Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities
    Published: 10-Feb-2020        Price: US 4500 Onwards        Pages: 585
    LeadingMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the French cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expans......
  • Succeeding in the 2020 Germany Cancer Diagnostics Market: Supplier Shares and Sales Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities
    Published: 10-Feb-2020        Price: US 4500 Onwards        Pages: 585
    LeadingMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the German cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expans......
  • Succeeding in the 2020 Italy Cancer Diagnostics Market: Supplier Shares and Sales Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities
    Published: 10-Feb-2020        Price: US 4500 Onwards        Pages: 570
    LeadingMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the Italian cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expan......
  • Succeeding in the 2020 Japan Cancer Diagnostics Market: Supplier Shares and Sales Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities
    Published: 10-Feb-2020        Price: US 4500 Onwards        Pages: 590
    LeadingMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the Japanese cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expa......
  • Succeeding in the 2020 Spain Cancer Diagnostics Market: Supplier Shares and Sales Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities
    Published: 10-Feb-2020        Price: US 4500 Onwards        Pages: 565
    LeadingMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the Spanish cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expan......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs